Diphencyprone

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Generic Name
Diphencyprone
DrugBank Accession Number
DB12173
Background

Diphencyprone has been used in trials studying the treatment and basic science of Melanoma, Ultraviolet Rays, Immunosuppression, Neoplasm Metastasis, and Hypersensitivity, Delayed, among others.

Type
Small Molecule
Groups
Investigational
Structure
Weight
Average: 206.244
Monoisotopic: 206.073164942
Chemical Formula
C15H10O
Synonyms
  • Diphenylcyclopropenone

Pharmacology

Indication

Not Available

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Associated Conditions
Indication TypeIndicationCombined Product DetailsApproval LevelAge GroupPatient CharacteristicsDose Form
Treatment ofAlopecia areata (aa)••• •••••••••••••
Treatment ofViral warts••• •••••••••••••
Contraindications & Blackbox Warnings
Prevent Adverse Drug Events Today
Tap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events with our Clinical API
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!
See the data
Improve decision support & research outcomes with our structured adverse effects data.
See a data sample
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
Not Available

Categories

Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as benzene and substituted derivatives. These are aromatic compounds containing one monocyclic ring system consisting of benzene.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Benzene and substituted derivatives
Sub Class
Not Available
Direct Parent
Benzene and substituted derivatives
Alternative Parents
Cyclic ketones / Organic oxides / Hydrocarbon derivatives
Substituents
Aromatic homomonocyclic compound / Cyclic ketone / Hydrocarbon derivative / Monocyclic benzene moiety / Organic oxide / Organic oxygen compound / Organooxygen compound
Molecular Framework
Aromatic homomonocyclic compounds
External Descriptors
cyclopropenone (CHEBI:53074)
Affected organisms
Not Available

Chemical Identifiers

UNII
I7G14NW5EC
CAS number
886-38-4
InChI Key
HCIBTBXNLVOFER-UHFFFAOYSA-N
InChI
InChI=1S/C15H10O/c16-15-13(11-7-3-1-4-8-11)14(15)12-9-5-2-6-10-12/h1-10H
IUPAC Name
diphenylcycloprop-2-en-1-one
SMILES
O=C1C(=C1C1=CC=CC=C1)C1=CC=CC=C1

References

General References
  1. NCATS Drugs: Diphencyprone [Link]
Human Metabolome Database
HMDB0251457
PubChem Compound
65057
PubChem Substance
347828461
ChemSpider
58568
ChEBI
53074
ChEMBL
CHEMBL1373467
ZINC
ZINC000001020197
Wikipedia
Diphenylcyclopropenone

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
4CompletedTreatmentVitiligo1
3RecruitingTreatmentAlopecia Areata (AA)1
1Active Not RecruitingTreatmentNeurofibromas, Cutaneous1
1CompletedBasic ScienceImmune Tolerance/Drug Effects / Immunosuppression / Type IV hypersensitivity reaction / Ultraviolet Rays1
1CompletedTreatmentMelanoma / Metastatic Cancer1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.00987 mg/mLALOGPS
logP3.72ALOGPS
logP3.85Chemaxon
logS-4.3ALOGPS
pKa (Strongest Basic)-8.3Chemaxon
Physiological Charge0Chemaxon
Hydrogen Acceptor Count1Chemaxon
Hydrogen Donor Count0Chemaxon
Polar Surface Area17.07 Å2Chemaxon
Rotatable Bond Count2Chemaxon
Refractivity64.42 m3·mol-1Chemaxon
Polarizability22.74 Å3Chemaxon
Number of Rings3Chemaxon
Bioavailability1Chemaxon
Rule of FiveYesChemaxon
Ghose FilterYesChemaxon
Veber's RuleYesChemaxon
MDDR-like RuleNoChemaxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
LC-MS/MS Spectrum - LC-ESI-qTof , PositiveLC-MS/MSsplash10-0a6r-0980000000-df3e8a9cbfaa4e19de32
MS/MS Spectrum - , positiveLC-MS/MSsplash10-0a6r-0980000000-df3e8a9cbfaa4e19de32
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSsplash10-0a4i-0090000000-18a9f18f4c827341999d
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSsplash10-0a4i-0090000000-b363abb6763696b228e6
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSsplash10-0a4i-0090000000-39248dd8d3f87e97c3a8
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSsplash10-0a4i-0090000000-b324116e710e19b4b96b
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSsplash10-0ufr-0900000000-250aa9f7fb0ffaf4dd03
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSsplash10-0fb9-0900000000-4d13884f8db52acc1d20
Predicted 1H NMR Spectrum1D NMRNot Applicable
Predicted 13C NMR Spectrum1D NMRNot Applicable
Chromatographic Properties
Collision Cross Sections (CCS)
AdductCCS Value (Å2)Source typeSource
[M-H]-152.7389137
predicted
DarkChem Lite v0.1.0
[M-H]-152.4907137
predicted
DarkChem Lite v0.1.0
[M-H]-146.73073
predicted
DeepCCS 1.0 (2019)
[M+H]+150.8389137
predicted
DarkChem Lite v0.1.0
[M+H]+150.7039137
predicted
DarkChem Lite v0.1.0
[M+H]+149.1263
predicted
DeepCCS 1.0 (2019)
[M+Na]+150.8702137
predicted
DarkChem Lite v0.1.0
[M+Na]+150.3559137
predicted
DarkChem Lite v0.1.0
[M+Na]+155.03883
predicted
DeepCCS 1.0 (2019)

Drug created at October 20, 2016 21:32 / Updated at December 03, 2022 09:37